Biochemical markers for predicting chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use;I marcatori biochimici nella valutazione della cardiotossicità da farmaci antineoplastici: Analisi sistematica della letteratura e raccomandazioni per il loro utilizzo

Giornale Italiano di Cardiologia

Volumn 7, Issue 9, 2006, Pages 604-611

  Dolci, Alberto ^a   Dominici, Roberto ^a   Cardinale, Daniela ^b   Sandri, Maria Teresa ^b   Panteghini, Mauro ^a,c  

^a Laboratorio Analisi Chimico Cliniche   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiotoxicity; Natriuretic peptides; Troponinu

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BLEOMYCIN; BUSULFAN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NATRIURETIC FACTOR; NAVELBINE; PACLITAXEL; PENTOSTATIN; RETINOIC ACID; RITUXIMAB; TENIPOSIDE; TRASTUZUMAB; TROPONIN; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MEDICAL LITERATURE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TROPONIN;

EID: 33845507311     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Micheli A, Mugno E, Krogh V, et al, for the EUROPREVAL Working Group. Cancer prevalence in European registry areas. Ann Oncol 2002; 13: 840-65.
2. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship - Genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25.
3. Kakavas PW, Ghalie R, Parrillo JE, Kaizer H, Barron JT. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant 1995; 15: 859-61.
4. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
5. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9.
6. Singal PK, Iliskovic N. Doxorubin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
7. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
8. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
9. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-78.
10. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.
11. Lipshultz SE, Colan SD. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. In: Bricker JT, Green DM, D'Angio GJ, eds. Long-term complications of treatment of children and adolescents for cancer. Philadelphia, PA: Wiley-Liss, 1993: 45-62.
12. McKillop JH, Bristow MR, Goris ML, Billingham ME. Bockemuehl K. Sensitivity and specificity of radionuclide ejection fraction in doxorubicin cardiotoxicity. Am Heart J 1983; 106: 1048-56.
13. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990; 8: 1806-10.
14. Meinardi MT, van der Graaf WTA, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
15. Benvenuto GM, Ometto R, Fontanelli A, et al. Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003; 4: 655-67.
16. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25: 301-11.
17. Herman EH, Lipshultz SE, Ferrans VJ. The use of cardiac biomarkers to detect myocardial damage induced by chemotherapeutic agents. In: Wu AHB, ed. Cardiac markers. 2nd ed. Totowa, NJ: Humana Press, 2003: 87-109.
18. Adamcova M, Sterba M, Simunek T, et al. Troponin as a marker of myocardial damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005; 4: 457-72.
19. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992; 89: 942-9.
20. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521-47.
21. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-18.
22. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003; 10: 132-9.
23. Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition. Am J Clin Oncol 2001; 24: 425-8.
24. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
25. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-34.
26. Herman EH, Lipshultz SE, Rifai N, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998; 58: 195-7.
27. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-43.
28. Herman EH, Zhang J, Rifai N, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone- induced cardiotoxicity. Cancer Chemother Pharmacol 2001; 48: 297-304.
29. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004; 68: 163-7.
30. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-22.
31. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-5.
32. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248-52.
33. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-22.
34. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.
35. Lipshultz SE, Rifai N, Dalton VM, et al. The effects of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-53.
36. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracyclin cardiotoxicity. Ann Oncol 2005; 16: 798-804.
37. Panteghini M. The new definition of myocardial infarction and the impact of troponin determination on clinical practice. Int J Cardiol 2006; 106: 298-306.
38. Auner HW, Tinchon C, Quehenberger F, Linkesch W, Sill H. Troponins in prediction of cardiotoxic effects. Lancet 2001; 357: 808.
39. Feleszko W, Mlynarczuk I, Balbowiec-Iskra E, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000; 6: 2044-52.
40. Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002; 88: 183-8.
41. Simunek T, Klimtova I, Kaplanova J, et al. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotonoyl hydrazone in rabbits. Pharmacol Res 2005; 51: 223-31.
42. Emdin M, Clerico A, Clemenza F, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005; 6: 430-46.
43. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-3.
44. Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 1998; 61: 347-53.
45. Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999; 62: 135-41.
46. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-63.
47. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4-9.
48. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-53.
49. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-34.
50. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21: 2349-56.
51. Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005; 7: 87-93.
52. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal proB-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-10.
53. Horacek JM, Pudil R, Tichy M, et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430-4.
54. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005; 19: 567-76.
55. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26: 1197-202.
56. Chen S, Garami M, Gardner DG. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 1999; 34: 1223-31.
57. Bhatheja R, Taneja D, Bakhru M, et al. Paradoxical decrease in plasma N-terminal-proBNP (NT-proBNP) levels in patients receiving doxorubicin chemotherapy and declining left ventricular ejection fraction. (abstr) J Am Coll Cardiol 2006; 47: 66A.